Sitagliptin 50 Mg

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. Keep out of the reach of children.

Most common adverse reactions (incidence≥5%) are: upper respiratory tract infection, nasopharyngitis and headache.

This medicine may cause serious allergic reactions, including anaphylaxis, angioedema, or certain skin conditions. It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to decide if you should continue to take it. This medicine may cause hypoglycemia (low blood sugar). This is more common when this medicine is taken together with certain medicines. Low blood sugar must be treated before it causes you to pass out (unconsciousness). Talk to your doctor about the best way to treat low blood sugar. Stop taking Sitagliptin 50mg and call your doctor if you have symptoms of pancreatitis: severe pain in your upper stomach spreading to your back, with or without vomiting.

Product Information: Disit 50MG oral tablet, sitagliptin hydrochloride monohydrate 50MG oral tablet. Laboratorios Alter, SA (per AEMPS;Spain), C/Mateo Inurria 30, 28036 Madrid, Spain, 2019. Product Information: ZITUVIO oral tablets, sitagliptin oral tablets. Zydus Pharmacuticals (USA) Inc (per FDA), Pennington, NJ, 2023. Micromedex Drug Information Database.

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor. The activity of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) is limited by the enzyme DPP-4, which rapidly hydrolyzes incretin hormones to form inactive products. Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 and GIP. By stimulating the levels of active incretins, sitagliptin increases insulin release and reduces glucagon levels with glucose-dependent behavior. The glucose-dependent sitagliptin mechanism is different from the sulfonylureas mechanism, which increases insulin secretion even when glucose levels are low and can lead to hypoglycemia in patients with type 2 diabetes and normal patients.

Anti Diabetic